LONG-TERM (LT) THERAPY OF A FARNESOID X RECEPTOR (FXR) AGONIST OBETICHOLIC ACID (OCA) MAINTAINS BIOCHEMICAL RESPONSE IN PRIMARY BILIARY CIRRHOSIS (PBC)

被引：3

作者：

Hirschfield, G. ^{[1
]}

Kowdley, K. ^{[2
]}

Mason, A. ^{[3
]}

Luketic, V. ^{[4
]}

Gordon, S. ^{[5
]}

Vincent, C. ^{[6
]}

Mayo, M. ^{[7
]}

Pares, A. ^{[8
]}

Chapman, R. ^{[9
]}

Lindor, K. ^{[10
]}

Esguerra, M.

Eliot, L. ^{[11
]}

Shapiro, D.

机构：

[1] Univ Toronto, Toronto, ON, Canada

[2] Virginia Mason Med Ctr, Seattle, WA 98101 USA

[3] Univ Alberta, Edmonton, AB, Canada

[4] Virginia Commonwealth Univ, Richmond, VA USA

[5] Henry Ford Hlth Ctr, Detroit, MI USA

[6] Hop St Luc, CHUM, Montreal, PQ H2X 1P1, Canada

[7] UT SW Med Ctr, Dallas, TX USA

[8] Hosp Clin Barcelona, Barcelona, Spain

[9] John Radcliffe Hosp, Headington, England

[10] Mayo Clin, Rochester, MN USA

[11] LKAN Clin, San Diego, CA USA

来源：

JOURNAL OF HEPATOLOGY | 2012年 / 56卷

关键词：

D O I：

10.1016/S0168-8278(12)60964-7

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

952

引用

页码：S372 / S372

页数：1

共 50 条

[41] Good long-term survival of patients with primary biliary cirrhosis and biochemical features of autoimmune hepatitis overlap syndrome. Influence of ursodeoxycholic acid therapy
Pares, Albert
HEPATOLOGY, 2012, 56 : 1138A - 1139A
[42] Autoantibody status and histological variables influence biochemical response to treatment and long-term outcomes in Japanese patients with primary biliary cirrhosis
Nakamura, Minoru
Kondo, Hisayoshi
Tanaka, Atsushi
Komori, Atsumasa
Ito, Masahiro
Yamamoto, Kazuhide
Ohira, Hiromasa
Zeniya, Mikio
Hashimoto, Etsuko
Honda, Masao
Kaneko, Shuichi
Ueno, Yoshiyuki
Kikuchi, Kentaro
Shimoda, Shinji
Harada, Kenichi
Arai, Kuniaki
Miyake, Yasuhiro
Abe, Masanori
Taniai, Makiko
Saibara, Toshiji
Sakisaka, Shotaro
Takikawa, Hajime
Onji, Morikazu
Tsubouchi, Hirohito
Nakanuma, Yasuni
Ishibashi, Hiromi
HEPATOLOGY RESEARCH, 2015, 45 (08) : 846 - 855
[43] LONG-TERM THERAPY WITH BEZAFIBRATE AND URSODEOXYCHOLIC ACID IS INSUFFICIENT FOR PREVENTING DISEASE PROGRESSION IN PATIENTS WITH ADVANCED PRIMARY BILIARY CIRRHOSIS
Reig, A.
Sese, P.
Pares, A.
JOURNAL OF HEPATOLOGY, 2015, 62 : S806 - S806
[44] Durable Response in the Markers of Cholestasis through 18 Months of Open-Label Long Term Safety Extension Study of Obeticholic Acid in Primary Biliary Cirrhosis
Trauner, Michael H.
Nevens, Frederik
Andreone, Pietro
Mazzella, Giuseppe
Strasser, Simone
Bowlus, Christopher
Invernizzi, Pietro
Drenth, Joost
Pockros, Paul J.
Regula, Jaroslaw
Floreani, Annarosa
Hohenester, Simon
Luketic, Velimir A.
Shiffman, Mitchell L.
Van Erpecum, Karel J.
Vargas, Victor
Vincent, Catherine
Hansen, Bettina
MacConell, Leigh
Marmon, Tonya
Shapiro, David
GASTROENTEROLOGY, 2016, 150 (04) : S1073 - S1074
[45] The impact of ursodeoxycholic acid (UDCA) therapy with or without liver transplantation (OLT) on long-term survival in primary biliary cirrhosis.
Corpechot, C
Carrat, F
Bahr, A
Poupon, RE
Poupon, R
HEPATOLOGY, 2003, 38 (04) : 519A - 519A
[46] Chronic elevation of plasma fibroblast growth factor 19 in long-term farnesoid X receptor agonist therapy, a happy marriage or cause for oncological concern?
Schaap, Frank G.
Jansen, Peter L. M.
Damink, Steven W. M. Olde
HEPATOLOGY, 2018, 67 (02) : 782 - 784
[47] A Prospective Randomized Controlled Study of Long-Term Combination Therapy Using Ursodeoxycholic Acid and Bezafibrate in Patients With Primary Biliary Cirrhosis and Dyslipidemia
Hosonuma, Kenichi
Sato, Ken
Yamazaki, Yuichi
Yanagisawa, Masatoshi
Hashizume, Hiroaki
Horiguchi, Norio
Kakizaki, Satoru
Kusano, Motoyasu
Yamada, Masanobu
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 (03): : 423 - 431
[48] PATIENTS WITH PRIMARY BILIARY CHOLANGITIS TREATED WITH LONG-TERM OBETICHOLIC ACID IN A TRIAL-SETTING DEMONSTRATE BETTER TRANSPLANT-FREE SURVIVAL THAN EXTERNAL CONTROLS FROM THE GLOBAL PBC AND UK-PBC STUDY GROUPS
Perez, Carla Fiorella Murillo
Fisher, Holly
Hiu, Shaun
Adekunle, Femi
Bonacci, Martin
Mayne, Tracy
Malecha, Elizabeth Smoot
Ness, Erik
Van der Meer, Adriaan J.
Lammers, Willem
Trivedi, Palak
Battezzati, Pier Maria
Nevens, Frederik
Kowdley, Kris
Bruns, Tony
Cazzagon, Nora
Floreani, Annarosa
Mason, Andrew L.
Ponsioen, Cyriel
Pares, Albert
Invernizzi, Pietro
Carbone, Marco
Lleo, Ana
Mayo, Marlyn J.
Dalekos, George N.
Gatselis, Nikolaos K.
Thorburn, Douglas
Verhelst, Xavier
Gulamhusein, Aliya
Janssen, Harry L.
Lindor, Keith D.
Corpechot, Christophe
Jones, David
Mells, George
Hirschfield, Gideon
Wason, James
Hansen, Bettina E.
HEPATOLOGY, 2021, 74 (06) : 1389A - 1390A
[49] PATIENTS WITH PRIMARY BILIARY CHOLANGITIS TREATED WITH LONG-TERM OBETICHOLIC ACID IN A TRIAL-SETTING DEMONSTRATE BETTER EVENT-FREE SURVIVAL OUTCOMES THAN EXTERNAL CONTROLS FROM THE GLOBAL PBC AND UK-PBC STUDY GROUPS
Perez, C. Fiorella Murillo
Kowdley, Kris V.
Fisher, Holly
Hiu, Shaun
Adekunle, Femi
Mayne, Tracy
Malecha, Elizabeth Smoot
Ness, Erik
van der Meer, Adriaan J.
Lammers, Willem J.
Trivedi, Palak
Battezzati, Pier Maria
Nevens, Frederik
Bruns, Tony
Cazzagon, Nora
Floreani, Annarosa
Mason, Andrew L.
Ponsioen, Cyriel Y.
Pares, Albert
Londono, Maria
Invernizzi, Pietro
Carbone, Marco
Lleo, Ana
Mayo, Marlyn J.
Dalekos, George N.
Gatselis, Nikolaos
Thorburn, Douglas
Verhelst, Xavier
Gulamhusein, Aliya
Janssen, Harry L.
Lindor, Keith D.
Corpechot, Christophe
Jones, Dave E.
Mells, George
Hirschfield, Gideon
Wason, James
Hansen, Bettina E.
GASTROENTEROLOGY, 2022, 162 (07) : S1196 - S1196
[50] IMPROVED PROGNOSIS FOR PATIENTS WITH PRIMARY BILIARY CIRRHOSIS SHOWING RELEVANT BIOCHEMICAL RESPONSE TO UDCA. RESULTS OF A MULTICENTER LONG-TERM COHORT STUDY INVOLVING 375 PATIENTS
Kuiper, Edith M.
Hansen, Bettina E.
de Vries, Richard A.
den Ouden-Muller, Janna W.
van Ditzhuijsen, Theo J.
Haagsma, Els B.
Houben, Martin
Witteman, Ben J.
Van Erpecum, Karel J.
van Buuren, Henk R.
HEPATOLOGY, 2008, 48 (04) : 599A - 600A

← 1 2 3 4 5 →